Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia

Prediction of Psychosis in Adolescents and Young Adults at High Risk

(2010) Stephan Ruhrmann et al.   ARCHIVES OF GENERAL PSYCHIATRY

Psychosis reactivity to cannabis use in daily life: an experience sampling study

(2010) Cécile Henquet et al.   BRITISH JOURNAL OF PSYCHIATRY

Disruption of Frontal Theta Coherence by Δ9-Tetrahydrocannabinol is Associated with Positive Psychotic Symptoms

(2010) Paul D Morrison et al.   NEUROPSYCHOPHARMACOLOGY

Anandamide elevation in cerebrospinal fluid in initial prodromal states of psychosis

(2009) Dagmar Koethe et al.   BRITISH JOURNAL OF PSYCHIATRY

Inhibition of fatty-acid amide hydrolase and CB1 receptor antagonism differentially affect behavioural responses in normal and PCP-treated rats

(2009) Alexandre Seillier et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

Opposite Effects of Δ-9-Tetrahydrocannabinol and Cannabidiol on Human Brain Function and Psychopathology

(2009) Sagnik Bhattacharyya et al.   NEUROPSYCHOPHARMACOLOGY

Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb

(2009) Angelo A. Izzo et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Reduced Cortical Cannabinoid 1 Receptor Messenger RNA and Protein Expression in Schizophrenia

(2008) Stephen M. Eggan et al.   ARCHIVES OF GENERAL PSYCHIATRY

Treatment of schizophrenia in the 21st Century: beyond the neurotransmitter hypothesis

(2008) Donald P Rogers et al.   Expert Review of Neurotherapeutics

Endogenous cannabinoids in patients with schizophrenia and substance use disorder during quetiapine therapy

(2008) Stéphane Potvin et al.   JOURNAL OF PSYCHOPHARMACOLOGY

The orphan receptor GPR55 is a novel cannabinoid receptor

(2007) E Ryberg et al.   BRITISH JOURNAL OF PHARMACOLOGY

Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro

(2007) A Thomas et al.   BRITISH JOURNAL OF PHARMACOLOGY